Whitepaper: Monocyte activation test (MAT)
Posted: 26 June 2019 | Merck | No comments yet
For pharmaceutical companies, patient safety has always been the priority. That’s why pyrogen detection has become a mandatory Quality Control test for release of any parenteral drug.
With the Monocyte Activation Test, the only in vitro test for the detection of the full range of pyrogens (including endotoxin and Non-Endotoxin Pyrogens), it’s now time to move away from animal-based test for pyrogen detection. The new PyroMAT™ System provides pharma companies with a robust solution to make the move to in vitro Pyrogen Test with a ready-to use kit!
Pyrogens…a hot story
Adverse reactions to parenteral preparations have been described as early as the late 19th century, frequently termed “injection fever”. The first fever-causing agents, “pyrogens”, were identified in 1912 by Hort and Penfold, who were also the first to design a pyrogen test based on injection of material into rabbits.
Please read and download the full Whitepaper below:
Related content from this organisation
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
